Premaitha appoints former ERBA Diagnostics CEO to board

Molecular diagnostics group Premaitha Health on Thursday appointed Hayden Jeffreys to the board as group commercial director upon completion of directorate appointment due diligence.

Jeffreys has spent more than two decades working in the clinical diagnostics industry and held senior international commercial and operational roles with companies such as ERBA Group, Lab21 and Gen-Probe.

The AIM traded company said he has a track record of formulating and implementing commercial strategy, pushing businesses into the next stage of their global growth.

Lyn Rees, chief executive of Premaitha, said: "Hayden has an excellent understanding of the commercial dynamics of our business. He has a proven track-record of driving traction in new technologies within molecular diagnostics and a keen understanding of regulatory environments, which we will leverage as we seek to develop new partnerships and grow our footprint across new territories."

His most recent role was as chief operating officer at privately held early-stage diagnostic outfit Cambridge Epigenetix after having served as interim chief executive for ERBA Diagnostics, where he made a “significant impact on business performance”.

"I believe Hayden will be a valuable addition to the management team as we look to accelerate revenue growth and take advantage of a truly global opportunity," said Rees.

Premaitha’s shares were down 7.09% at 13.75p at 1257 BST.